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Abstract
Purpose Both asthma and obstructive sleep apnoea cause
sleep disturbance, daytime sleepiness and diminished quality
of life. Continuous positive airway pressure (CPAP) is effi-
cient in reducing symptoms related to sleep apnoea. Here we
report the impact of long-term use of CPAP on asthma
symptoms.
Methods A survey questionnaire was distributed to all of our
obstructive sleep apnoea patients with CPAP therapy in 2013.
We used the Finnish version of the Asthma Control Test™
(ACT) and a visual analogue scale (0 = no symptoms, 100 = se-
vere asthma symptoms). Asthma was defined as self-reported
physician-diagnosed disease and a special reimbursement for
asthma medication by the Social Insurance Institution.
Results We sent 2577 questionnaires and received 1586 answers
(61 %). One hundred ninety-seven patients were asthmatics with
a prevalence of asthma among CPAP users of 13 %. We studied
152 patients (58 females) whoseCPAP therapywas initiated after
starting asthma medication. Their mean (SD) age was 62 (10)
years, duration of CPAP 5.7 (4.7) years and their CPAP daily use
was 6.3 (2.4) h. Self-reported asthma severity decreased signifi-
cantly from 48.3 (29.6) to 33.1 (27.4) (p< 0.001), andACTscore
increased significantly from 15.35 (5.3) to 19.8 (4.6) (p < 0.001)
without a significant change in the body mass index (BMI). The
percentage of patients using rescue medication daily reduced
from 36 to 8 % with CPAP (P < 0.001).
Conclusions We noticed a significant decrease in asthma
symptoms with long-term use of CPAP in patients with both
asthma and obstructive sleep apnoea.
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Introduction
Symptoms of obstructive sleep apnoea (OSA), such as waking
up at night with breathing difficulties, snoring and witnessed
apnoeas, are common in patients with asthma [1–5]. However,
the exact prevalence of OSA in asthmatic patients is not
known but the incidence of OSA has been reported to be
approximately 2.5 times greater in asthma patients than those
without asthma [5, 6].
It has been suggested that OSA is an independent risk factor
for asthma exacerbation [7], and it has been recommended that
physicians evaluate symptoms that suggest OSA and consider
differential diagnostics, especially in unstable, poorly controlled
asthmatic patients, particularly those who are overweight or
obese [8].
The first-line therapy for moderate to severe OSA is contin-
uous positive airway pressure [CPAP], which is considered the
most effective therapy to suppress sleep apnoea-related symp-
toms. Clinical improvement of symptoms after CPAP treatment
is directly related to a major reduction in respiratory events and
their related consequences during sleep. Specifically, CPAP
eliminates or reduces the chronic intermittent hypoxia and sleep
fragmentation observed during apnoeic events [9].
In asthmatics with concomitant OSA, CPAP has been
shown in a prospective clinical study to have a positive impact
on asthma outcome such as improvement in daytime and
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night-time asthma symptoms, reductions in nocturnal broncho-
dilator use and marked improvement in mean peak expiratory
flow rates [6]. The aforementioned study was prospective but
short and included a limited number of patients.
Although the number of studies on asthma, asthma and
respiratory symptoms and OSA has been increasing, the con-
sequences of CPAP therapy on asthma is not fully understood.
The purpose of this study was to evaluate the prevalence of
current asthma among CPAP users and describe the effect of
long-term CPAP use on asthma symptoms.
Material and methods
This was a one-centre retrospective cross-sectional question-
naire study on respiratory symptoms and patient’s perspective
of CPAP therapy on respiratory symptoms in patients with
concomitant asthma and OSA. All the patients with diagnosed
obstructive sleep apnoea (OSA) (N = 2577) and current CPAP
therapy of more than 3 months duration in the sleep unit in the
Helsinki University Central Hospital were sent a questionnaire
in June–July 2013 (diagnosed OSA, current CPAP therapy
and self-reported physician diagnosed asthma formed the in-
clusion criteria) (Fig. 1). The exclusion criteria were asthma
diagnosed after starting CPAP therapy, use of CPAP for less
than 3 months and OSAwithout current CPAP therapy.
Asthma
Asthma was assessed as a self-reported physician-diagnosed
disease. In Finland, asthma is diagnosed according to the in-
ternational guidelines [10]. The criteria for reversible airway
obstruction are either a bronchodilator response in spirometry
(≥12 % and ≥200 ml) or moderate to severe bronchial
hyperreactivity or a bronchodilator response in peak expirato-
ry flow (PEF) recording (≥15 %), a diurnal variation in PEF
(≥20 %) or a FEV1/PEF decrease of ≥15 % in an exercise test
[11, 12].
Asthma severity was assessed by a visual analogue scale
(VAS) from 0 (no symptoms) to 100 (severe asthma symp-
toms). In addition, the patients fulfilled the Asthma Control
Test® (ACT) concerning their symptoms (score between 5
and ≤19 uncontrolled asthma, 20–24 well-controlled asthma,
and score = 25 totally controlled asthma). Patients reported
their asthma symptoms retrospectively both before CPAP
treatment and during the last 4 weeks using both ACT and
VAS [13, 14]. ACT questions included use of asthma medi-
cation (During the past 4 weeks, how often have you used
rescue inhaler or nebulizer medication?). The use of asthma
medication was reported before of CPAP treatment and during
the last 4 weeks. Asthma patients whose diagnosis was ac-
complished after starting CPAP therapy were excluded from
the analyses.
Smoking status was assessed by the questionnaire. From
the patient’s file, we obtained values for body mass index and
data concerning the use of CPAP and the chronology of asth-
ma. We also analysed changes in body mass index (BMI)
using the information on weight and height in the medical
records at the time of starting CPAP therapy and at the time
of the questionnaire study.
Obstructive sleep apnoea
The baseline sleep studies were mainly performed with the
help of home polygraphy. In few cases, the diagnosis of
OSA was done with the help of an in-lab polysomnography
(PSG) or a home PSG. To avoid confusion related to the dif-
ferences in OSA diagnostic method, we included in this study
only patients with a home polygraphy. We offered CPAP ther-
apy to patients with a respiratory event index (REI) >15/h
during a sleep study (out-of-centre sleep test) and to patients
with REI 5–14 and symptoms related to OSA [15]. The def-
inition for apnoea was absence of nasal or buccal flow >10 s.
The definition for hypopnoea was a decrease of nasal flow of
at least 50 % for at least 10 s or a decrease of saturation of at
least 3 % [16].
CPAP therapy was initiated mainly at home with an auto-
matic PAP device (ResMed, Sydney, Australia), and titration
was controlled by oximetry. The pressure was set to start au-
tomatically, from 4 cmH2O up to maximum of 20 cmH2O.
The treatment effect was controlled by oximetry, and normal-
ized results were considered if mean SPO2 values were at least
95 % and ODI4 was less than five per hour [17]. The effect of
CPAP therapy on OSA was controlled at 1 week, 3 months
and then yearly as previously described [17]. For this study,
we only used those who had had CPAP therapy for more than
OSA and CPAP,
N = 2577, sent ques onnaires
in June-July 2013
1586 returned ques onnaires
(61.5%)
197 asthma p ents (12.7% out of 
1586) 
19 asthma p ents were
excluded since asthma was
diagnosed er star ng CPAP
152 asthma p ents whom basic
sleep study was done by a home
polygraphy were included
Fig. 1 Flowchart of patient recruitment for sleep apnoea and asthma
patients
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3 months. Data were obtained from the memory of the CPAP
device at each control visit.
The Helsinki University Central Hospital gave ethics per-
mission (number §19 2/2013, date 25.5.2013) to organize the
study, and the informed consent forms were included in the
questionnaires.
Statistical analysis
Shapiro-Wilk’s test (p > 0.05) and a visual inspection of their
histograms, normal Q-Q plots and box plots showed that the
exam scores were approximately normally distributed for the
asthma control test score at baseline for both men and women,
with a skewness of −0.287 (SE = 0.274) and a kurtosis of
−0.960 (SE = 0.541) for men and a skewness of 0.366
(SE = 0.365) and a kurtosis of −0.421 (SE = 0.717) for women.
The ANOVA method was used to compare differences in
ACT scores [13]. We used Student’s t test for continuous var-
iables with normal distribution and the chi-square tests for
categorical variables. If the assumption, in the chi-square test,
was violated, we used Fisher’s exact test. A p value <0.05 was
considered statistically significant.
The ACT scores before and after CPAP therapy were first
analysed in the total study population and then in the subgroup
of asthma patients. We divided patients according to the clin-
ically significant modification in their ACT score into two
groups: ΔACT ≥ 3 group and ΔACT < 3 group [18].
A multivariate regression analysis was used to define factors
that may predict modifications in asthma symptoms measured
by the ACT. We run multivariate linear regressions forΔACT
using ACT baseline, CPAP daily use, age, gender, CPAP ther-
apy duration, change in BMI, current smoking, chronic rhinitis,
REI baseline, REI CPAP, BMI baseline and the baseline sleep
study PSG or polygraphy.
IBM SPSS Statistics software (version 22.0.0.1) (IBM
Corporate, New York, USA) was used to compute differences
in demographic, clinical and measured variables.
Results
We received altogether 1586 answers (61.5 %). The responders
(those who returned the questionnaire) were older than the non-
responders (those who did not return the questionnaire), 60 (SD
13) vs. 58 (12) years, respectively (p < 0.001). Of the re-
sponders, 27 % were women and 45 patients had discontinued
using CPAP therapy by the time of questioning. A total of 1530
patients had OSA and a current CPAP treatment (Fig. 1). Of
these, 178 had a self-reported physician-diagnosed asthma with
special reimbursement for asthma medication in whom asthma
diagnosis had been done prior to CPAP therapy. We included
152 patients whose basic sleep study was done by a home
polygraph. The mean age of the patients with both asthma
and OSA was 62 years (10 years), and 38 % of the patients
were women. All the patients had used CPAP therapy amean of
5.9 years (4.8) for 6.0 h/day (2.5), while the respective numbers
for both asthma and OSA patients were 5.7 years (4.7) and
6.3 h/day (2.4) (p value ns). Minimum of the CPAP use was
0 h and maximum 10.2 h/day, median 6.90 h and percentiles of
CPAP use were 5.5 (25th percentile), 6.90 (50th percentile) and
8.0 (75th percentile) in patients with asthma and OSA. CPAP
treatment was effective in reducing the apnoea and hypopnoea
index from 41.2 to 3.5/h.
We excluded 26 patients as their baseline sleep studies
were performed with the help of an in-lab polysomnography
(PSG) or home PSG. We found no significant differences
between PSG and home polygraph groups regarding their
age [F(2, N = 178) = 0.15, p = 0.99], gender [χ2 (2,
N = 178) = 2.83, p = 0.24], CPAP daily use [F(2,
N = 178) = 0.25, p = 0.78], scores of ACT baseline [F(2,
N = 178) = 0.39, p = 0.68] or ACT with CPAP [F(2,
N = 178) = 0.10, p = 0.91].
The severity of asthma symptoms measured by the
VAS score decreased from 50.8 (SD 30.7) at baseline be-
fore CPAP treatment to 33.6 (25.9) with CPAP in women
[t (39) = 4.007, p = 0.000]) and in men from 46.8 (29.1) to
32.9 (28.4) [t (69) = 6.483, p = 0.000]. In both women and
men, it also decreased significantly from 48.3 (29.6) to
33.1 (27.4) [t (109) = 7.311, p = 0.000] (Fig. 2). We found
the same trend concerning the self-reported asthma sever-
ity expressed by the ACT score. It increased significantly
from the baseline at 15.3 (5.3) to 19.8 (4.2) with CPAP in
women [t (33) = −6.677, p = 0.000] (Fig. 3) and in men
from 17.2 (5.6) to 19.1 (4.9) [t (67) = −4.373, p = 0.000],
respectively. Moreover, we found a significant correlation
between the values of the ACT at baseline and those of the
asthma severity at baseline [r (102) = −0.721, p = 0.000].
The mean baseline BMI was 37.2 (8.7) kg/m2 in women
and 33.8 (6.0) kg/m2 in men. There was no statistically signif-
icant change in the BMI during the time course of CPAP
therapy, neither in women nor in men [t (145) = −0.277,
p = 0.782].
The percentage of patients reporting no night-time symp-
toms was 28 % at baseline and increased significantly [χ2 (1,
N = 103) = 19.232, p = 0.000] (p < 0.001) with CPAP to 55%.
Moreover, we noticed a similar amelioration concerning the
percentage of patients using rescue medication daily, with a
significant reduction from 36 to 8 % with CPAP (p < 0.001).
As a value of 3 in the ACT score means a clinically signif-
icant change [18], we divided our patients into one group with
an ACT change of three or more (ΔACT ≥ 3) and another
group with an ACT change of less than three (ΔACT < 3).
We did not find a statistically significant association related to
age, daily CPAP use, duration of CPAP therapy, severity of
sleep apnoea, values of residual REI or values of BMI at
baseline between these two groups. Moreover, the presence
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of current smoking, COPD or chronic rhinitis did not differ
significantly between the ΔACT ≥ 3 and ΔACT < 3 groups
(Table 1). Interestingly, women were found significantly more
often (49%) in theΔACT ≥ 3 group compared to the ΔACT< 3
group (18 %) [χ2 (1, N = 102) = 11.294, p = 0.001]. The same
tendency was noticed in patients with a lower ACT score at
baseline [t (100) = −6.222, p = 0.000] and in patients with a
higher VAS asthma severity score [t (99) = 3.095, p = 0.003].
The absolute value of the BMI at baseline was not associated
with the change in the ACT with CPAP [t (97) = 1.063,
p = 0.290]. Nevertheless, a slight decrease in weight with
CPAP (mean of −1.6 kg) was associated with a significant
increase in the ACTwith CPAP [t (97) = −2.740, p = 0.007].
We performed a multivariate regression analysis to define
factors that may predict asthma symptom changemeasured by
the ACT. Table 2 shows age, duration of CPAP therapy, daily
CPAP use, change in bodyweight, smoking status, chronic
rhinitis, severity of OSA measured by REI, or the efficacy of
CPAP on AHI values or the type of the baseline sleep study
(polysomnography or a polygraphy) did not show a signifi-
cant relation to the ACT modification.
Meanwhile, the patient’s gender (female), values of BMI at
baseline and especially values of ACTat baseline were significant
factors in predicting ACT modifications. The regression analysis
showed that values of ACT at baseline could significantly predict
35 % of the ACT modification with long-term CPAP [p = 0.000,
R2 = 0.346]. The regression equation was ŶΔACT = 11.220 +
(−0.502) ACT baseline.
Discussion
We found a prevalence of self-reported asthma of 13% among
long-term CPA users. In this population, long-term CPAP use
reduced asthma symptoms measured both by a VAS and ACT
significantly. Self-reported asthma severity decreased from
47.6 to 31.6 using the VAS scale during the CPAP treatment.
Likewise, the self-reported ACT score increased from 16.5 to
19.3 during the CPAP treatment (p < 0.001), showing better
asthma control during the CPAP treatment, whereas the BMI
of the patients stayed unchanged.
This is the first study showing the long-term effect of CPAP
on asthma symptoms in a large patient population. Further, the
asthma diagnosis was based on both symptoms, airway re-
versibility shown in lung function measurements, as well as
a response to asthma medication. On the other hand, the effect
of CPAP treatment on bronchial hyperreactivity conflicts with
reports of either a lack of effect on bronchial hyperreactivity
[19] or even a negative effect [20]. In the latter study, bronchial
Fig. 2 Self-reported asthma severity on a visual analogue scale (0–
100 mm) before and during CPAP treatment for OSA
Fig. 3 Asthma control test score results before and during CPAP
treatment
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hyperreactivity was increased in 57 OSA patients after 3 weeks
of CPAP therapy compared to the baseline.
Previous studies on asthma and OSA have been smaller, in-
cluding 9–50 patients, and have had a shorter duration of CPAP
treatment ranging from 2weeks to 6 months [19, 21–23], where-
as we had altogether 178 patients with self-reported physician-
diagnosed asthma and current CPAP treatment for OSA, whose
CPAP therapy had continued for a mean of 5.5 years.
In the earlier studies, night-time asthma symptoms and noc-
turnal bronchodilator use were reported to be reduced by CPAP
treatment in asthma patients [21, 22]. Further, daytime asthma
symptoms have been reported to decrease and asthma-specific
quality of life to improve due to CPAP therapy [19, 21, 23]. Our
results were in accordance with the previous study results al-
though our study was a retrospective questionnaire study with-
out objective pulmonary function test measurements before and
Table 1 Comparison of
clinical characteristics,
asthma severity, OSA
severity and CPAP use in
the group withΔACT ≥ 3
vs. the group with
ΔACT < 3
ACT difference (baseline − CPAP) = ΔACT
≥3 <3
Mean SD Mean SD t df p value
Age, years 63.2 8.3 63.1 10.2 0.085 100 0.932
CPAP daily use (hours) 7.1 1.5 6.7 1.6 1.226 100 0.223
CPAP since (days) 2153 1682 2123 1692 0.089 100 0.929
REI baseline 42.0 26.0 40.2 25.7 0.338 93 0.736
REI residual 3.4 3.3 2.8 2.3 1.022 92 0.310
BMI baseline (kg/m2) 35.1 7.7 33.7 5.6 1.063 97 0.290
Bodyweight change (CPAP − baseline, kg) −1.6 11.0 3.5 6.8 −2.740 97 0.007
ACT baseline 13.6 4.0 19.5 5.4 −6.222 100 0.000
Asthma severity VAS baseline 56 27 39 28 3.095 99 0.003
n (%) n (%) (χ2) df p value
Women 25 (49) 9 (18) 11.294 1 0.001
Current smoker 7 (14) 5 (10) 0.378 1 0.539
COPD 13 (26) 14 (28) 0.050 1 0.822
Chronic rhinitis 16 (31) 21 (41) 1.060 1 0.303
ACTmeans asthma control test: 5 = severe symptoms, 25 = no symptoms; asthma severity measured by a visual analogue
scale, 0 = no symptoms, 100 = severe asthma symptoms
REI respiratory event index
Table 2 Predictors of
amelioration of asthma symptoms
with the long-term CPAP therapy
with a multivariate regression
analysis
Model Unstandardized
coefficients
Standardized
coefficients
t p
value
B Std.
error
Beta
(Constant) 22.926 5.505 4.164 .000
Asthma control test, ACT (baseline) −0.474 0.078 −0.543 −6.091 .000
CPAP daily use 0.253 0.272 0.081 0.932 .354
Age −0.081 0.049 −0.156 −1.637 .106
Gender −2.125 0.954 −0.211 −2.228 .029
CPAP treatment duration 0.000 0.000 −0.048 −0.537 .593
Change in body weight
(baseline − CPAP)
−0.086 0.049 −0.173 −1.760 .082
Current smoking 0.224 1.330 0.015 0.168 .867
Chronic rhinitis −0.054 0.897 −0.005 −0.060 .952
Respiratory event index, REI
(baseline)
0.016 0.019 0.087 0.864 .390
REI (CPAP) 0.194 0.152 0.115 1.278 .205
Body mass index (baseline) −0.197 0.078 −0.280 −2.530 .013
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during CPAP therapy. Both VAS and the ACT test have been
used when estimating asthma symptoms and asthma control
even though sleep disturbance might be associated to either
OSA or asthma or both. Here, the number of patients using
rescue medication two to three times per week reduced signif-
icantly from 19 to 13 % with CPAP treatment, and those not
needing rescue medication significantly increased from 33 to
36 % (p < 0.001) which was the level of asthma medication
follow-up that was estimated possible when planning the study.
In a prospective setting, a number of per oral steroid courses per
year and a dose of inhaled corticosteroids should be followed.
However, even if the asthma medication would be analysed
further, it is according to patients’ reports. The actual count of
used medication is followed only in clinical trials and else-
where (both in the medical records and in clinical studies),
the information is based on the patient report. Since direct-
ly observed treatment is not used in asthma treatment, there
is no absolute method for medication treatment adherence.
Further, the 13 % prevalence of asthma among CPAP users
in here is almost twice the reported prevalence of asthma
patients with special reimbursement for medication in
Finland (6.6 % in the year 2011) [24].
Neutrophilic inflammation of lower airways demonstrated
by sputum samples has been reported in OSA patients without
CPAP treatment [25]. Salerno et al. hypothesized that this
might be caused by intermittent upper airway obstruction
and mechanical mucosal stress. Further, neutrophilic lower
airway inflammation would lead to airway obstruction. In
the study of Salerno et al., BMI or obesity was not correlated
to sputum neutrophilia but OSA was. Obesity and sleep ap-
noea are more likely to be associated with a neutrophilic asth-
ma phenotype than an allergic and/or eosinophilic asthma
phenotype, offering an explanation for the reduced probability
of reaching an optimal asthma control level with traditional
asthma therapy such as inhaled corticosteroids, long-acting
bronchodilators and antileukotrienes [23, 26, 27]. Obesity
has been associated with asthma both as a risk factor for asth-
ma and as a modifying factor of the disease [28, 29]. Since this
was a questionnaire study we did not have the option of study-
ing sputum samples to differentiate between eosinophilic and
neutrophilic asthma phenotypes. However, our results are in
agreement with earlier ones [30] in which obese patients did
not lose weight after the initiation of CPAP therapy. Further,
the improvements in asthma control in our patients were not a
result of weight loss.
The positive effect of CPAP on respiratory symptoms was
greater in women and in those with poorer ACT and VAS
values. Asthma is more common in women, and OSA is more
often found in men [26]. Obesity is associated with both OSA
and more severe asthma. OSA patients with concomitant asth-
ma have probably more respiratory symptoms than patients
with only OSA. These results are suggestive for and additive
treatment option to traditional asthma medication in obese
asthmatic women and especially in patients with both asthma
and OSA.
The benefits of CPAP treatment on asthma symptoms in
asthma and OSA patients are multiple. CPAP therapy has
been suggested to reduce systemic inflammation associat-
ed with OSA. CPAP treatment has been reported to de-
crease hypoxia and oxidative stress, to decrease neutrophil
superoxide dismutase generation and superoxide release,
and to lower CRP and vascular endothelial growth factor
(VEGF) levels [6]. One of the mechanisms of CPAP ther-
apy that may be effective in asthma is improving the acinar
ventilation heterogeneity that has been shown to exist even
during inhaled corticosteroid therapy [31]. Decreasing ac-
inar ventilation heterogeneity might simply lead to im-
proved ventilation but also secondarily decrease the local
inflammation process. Further, improvements in reflux
syndrome might contribute to reducing both any night-
time respiratory symptoms and also specifically night-
time asthma symptoms [6, 32].
In our study, none of the following variables (age, daily
CPAP use, duration of CPAP therapy, severity of sleep ap-
noea, values of residual REI) were associated with an increase
in ACTscores of three ormore. Nevertheless, a slight decrease
in BMI with CPAP was associated with a significant increase
in ACTwith CPAP, pointing to the role of body weight regu-
lation in the pathogenesis of asthma symptoms. In addition,
female gender, ACT baseline and BMI baseline values were
predictive for a greater response (measured by ACT) to CPAP
therapy.
The study has some limitations as it is a questionnaire
study. Moreover, we did not report the effect on pulmonary
function test results of CPAP therapy, nor comorbidity,
which may influence asthma symptoms. We hypothesize
that regular CPAP users are motivated patients, and moti-
vation may also increase compliance to other treatments
such as asthma medication. In addition, our reported re-
sults concerning asthma severity are both self-reported
and retrospective, both of which include a possibility of
recall bias. Thus, a prospective follow-up study with a
control group should be performed to validate these study
results. Those who answered our questionnaire were com-
pliant CPAP users (6.3 h/day). The compliance in this
study was greater than what we have reported previously
(5.6 h ± 1.5) [33], probably because of high prevalence of
asthma in this study. It is possible that asthma patients with
OSA are more symptomatic and thus also more compliant
than average CPAP users. This may have had a positive
impact on their answers to asthma symptoms before and
during CPAP therapy compared to those with OSA and
asthma but no CPAP therapy. Further, our results cannot
be generalized to the overall asthma population but only
to those with concomitant sleep apnoea syndrome.
However, a recent study on patients with severe asthma
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by D’Amato et al. reported improvement in asthma con-
trol with CPAP therapy and reduction in PEF variability
in patients without OSA [34]. In addition, these analyses
and results are limited to the patients with OSA diagnosed
with an ambulatory home polygraphy and thus may un-
derestimate the true prevalence or severity of OSA in
these patients [35]. Further, no formal in-lab CPAP titra-
tion was performed and instead CPAP therapy was initi-
ated at home with an automatic PAP device and titration
was controlled by oximetry. In a prospective setting, the
use of an in-lab PSG and an in-lab CPAP titration would
be more exact methods and thus recommended.
In conclusion, we noticed a statistically and clinically
significant improvement in asthma control in patients
using CPAP. This reduction in self-reported asthma sever-
ity could not be interpreted as a change in BMI. If asthma
control is not achieved in obese patients, then the possibil-
ity of coexisting OSA should be assessed and CPAP ther-
apy offered.
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